The National Science Foundation (NSF) has awarded a $450,000 Project Grant under the Engineering program (CFDA 47.041) to the University of Texas at Austin. The grant supports the development of novel biosensing tools for therapeutic drug monitoring, specifically targeting the antipsychotic medication clozapine. The key objectives are to:
- Select and optimize aptamers that bind clozapine with high affinity and specificity.
- Establish highly reliable aptamer-based sensing platforms, including a personal glucose meter-based detection system and a nanopipette sensing platform for digital quantification of clozapine.
- Conduct outreach programs to train K-12 students on the new biosensing technologies and encourage them to pursue STEM careers.
This 3-year project, running from January 1, 2025 to December 31, 2027, aims to create more sensitive, reliable, and affordable tools for monitoring clozapine blood concentrations compared to existing colorimetric assays. No subawards are planned under this grant.
Generated 3/4/25, 5:44 AM